Cyclin-Dependent Kinase (CDK) Inhibitors Therapeutics Pipeline Projects Vast Growth Ahead     |    CAD Software Market to Reach $11,097 Million by 2023     |    Friedreich’s Ataxia (FRDA) Therapeutics Pipeline to Receive Various Drug Designations from the USFDA and EMA in the Coming Years
P&S Market Research - A market research firm

Acute Lymphoblastic Leukemia (ALL) Therapeutics Market

P&S Market Research-Acute Lymphoblastic Leukemia Therapeutics Market report

Global Acute Lymphoblastic Leukemia (ALL) Therapeutics Market - Epidemiology Analysis, Therapy, Development, Growth and Demand Forecast to 2023

Delivery : 24-72 Working Hours
Report Code: LS10894
Available Format: pdf

The global acute lymphoblastic leukemia therapeutics market is expected to witness considerable growth in the coming year since new drug formulations are proving to be the most effective treatment for cancer. An increasing awareness regarding cancer treatment, various technological advancements, high demand for safe and effective medications and high prevalence of cancer, are driving the growth of the global acute lymphoblastic leukemia therapeutics market. The regulatory bodies are also supporting the growth of the global market by providing funding, designations and grants to speed up the drug development process.

According to National Cancer Institute, which is a part of the U.S. National Institutes of Health, acute lymphocytic leukemia, also known as acute lymphoblastic leukemia, is a cancer that starts from the early version of white blood cells called lymphocytes in the bone marrow (the soft inner part of the bones, where new blood cells are made). Leukemia cells usually invade the blood fairly quickly and can then spread to other parts of the body, including the lymph nodes, liver, spleen, central nervous system (brain and spinal cord), and testicles (in males). Other types of cancer can also occur in these organs and then spread to the bone marrow, but these cancers are not leukemia.

The pipeline of acute lymphoblastic leukemia contains GRASPA (Erythrocytes Encapsulating L-asparaginase), a Phase I drug candidate of ERYtech Pharma, Inc. GRASPA is an encapsulated L-asparaginase product, using the company’s proprietary ERYCAPS platform technology for the treatment of acute lymphoblastic leukemia in adults and children. GRASPA causes systemic degradation of asparagine and inhibits the growth and survival of cancer cells.

Spectrum Pharmaceuticals, Inc. markets Marqibo for the treatment of acute lymphoblastic leukemia. It is a targeted intravenous formulation of vincristine sulfate. It acts as a tubulin polymerization inhibitor. The product was launched in the U.S. for acute lymphoblastic leukemia, in 2013.

Certain chemotherapy medications such as Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Chlorambucil, Procarbazine Prednisolone, Mustine, Vincristine, Etoposide, Cyclophosphamide, Gemcitabine, Cisplatin and Cytarabine have been well established as a conventional method. Immunotherapy, combination therapy, monoclonal antibodies and steroids are showing good results for the treatment of acute lymphoblastic leukemia.

Pharmaceutical companies are collaborating for research and development of acute lymphoblastic leukemia. In January 2016, Spectrum Pharmaceuticals and Servier collaborated for the development and commercialization of Spectrum's four haemato-oncology drugs, including Marqibo. As part of this partnership, Spectrum granted the exclusive rights to Servier for the development and commercialization of vincristine liposomal in Canada. Spectrum received a total amount of $6.0 million as upfront payment, plus development milestone payments and royalties based on net product sales. Also, increasing awareness regarding the treatment and rising incidence of the disease has been driving the market growth. However, high cost of treatment, increased cost associated with the research and development and the side effects associated with the treatment act as key barriers for growth of the global market.

Geographically, North America is expected to be the largest market for acute lymphoblastic leukemia, owing to a large number of research and development activities, high healthcare expenditure, and increasing prevalence of cancer. According to National Cancer Institute, estimated new cases of acute lymphoblastic leukemia were 6,590 and estimated deaths were 1,430 in 2016, in the U.S. The U.S. contributed the largest revenue to the North American market in 2016, and it is expected to remain the largest market, globally, during the forecast period.

Some of the key players operating in the global acute lymphoblastic leukemia treatment market are Spectrum Pharmaceuticals, Inc., Sigma-Tau Pharmaceuticals, Inc., ERYtech Pharma, Pfizer, Inc., Amgen, and Takeda Pharmaceutical Company Limited.

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

Group License

Group License authorizes access of the publication upto 5 users.

Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.


Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment